This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-outlook: Archive
BlackSky Technology Inc. (BKSY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
BlackSky Technology (BKSY) delivered earnings and revenue surprises of -6.12% and -0.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BKSYNegative Net Change DUOTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Cipher Mining Inc. (CIFR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cipher Mining (CIFR) delivered earnings and revenue surprises of 0.00% and -7.20%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CIFRNegative Net Change UMACPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Lifetime Brands (LCUT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Lifetime Brands (LCUT) delivered earnings and revenue surprises of -194.12% and -4.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
LCUTPositive Net Change AMRKNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Lee Enterprises, Incorporated (LEE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Lee Enterprises (LEE) delivered earnings and revenue surprises of -138.46% and -4.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
LEENegative Net Change CDZIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of +40.00% and +7.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CRMDNegative Net Change HOWLNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of +51.61% and +118.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
GLUEPositive Net Change IRDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
GoHealth (GOCO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
GoHealth (GOCO) delivered earnings and revenue surprises of +52.69% and -16.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
GOCONegative Net Change NKSHPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of +800.00% and +37.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
IRWDPositive Net Change PRPHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +100.00% and +33.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
AKBAPositive Net Change TBPHPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Arbe Robotics Ltd. (ARBE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Industrial Tech Acquisitions (ARBE) delivered earnings and revenue surprises of +25.00% and -8.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ARBENo Net Change VRMENegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Backblaze, Inc. (BLZE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Backblaze (BLZE) delivered earnings and revenue surprises of +120.00% and +2.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BLZEPositive Net Change RUMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Pagaya Technologies Ltd. (PGY) Lags Q2 Earnings Estimates
by Zacks Equity Research
Pagaya Technologies Ltd. (PGY) delivered earnings and revenue surprises of -7.25% and +0.79%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PGYNegative Net Change WULFPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Chicago Atlantic Real Estate Finance, Inc. (REFI) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Chicago Atlantic Real Estate Finance (REFI) delivered earnings and revenue surprises of +13.33% and +3.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
REFIPositive Net Change ATLCPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -22.12% and -21.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
RGNXNegative Net Change COYANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Americold Realty Trust Inc. (COLD) Q2 FFO and Revenues Top Estimates
by Zacks Equity Research
Americold Realty Trust (COLD) delivered FFO and revenue surprises of +5.88% and +0.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
COLDNegative Net Change STRWPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
ConocoPhillips (COP) Tops Q2 Earnings Estimates
by Zacks Equity Research
ConocoPhillips (COP) delivered earnings and revenue surprises of +4.41% and -1.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
COPPositive Net Change EPSNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -30.77% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
INSMPositive Net Change ARCTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Appian (APPN) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Appian (APPN) delivered earnings and revenue surprises of +100.00% and +6.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
APPNNegative Net Change DCBOPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Gogo (GOGO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Gogo (GOGO) delivered earnings and revenue surprises of +8.33% and +2.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
GOGOPositive Net Change CMBMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Kimbell Royalty (KRP) Lags Q2 Earnings Estimates
by Zacks Equity Research
Kimbell Royalty (KRP) delivered earnings and revenue surprises of -85.71% and +6.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
KRPPositive Net Change GLNGNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
N-able (NABL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
N-able (NABL) delivered earnings and revenue surprises of +22.22% and +4.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
NABLNegative Net Change LNZANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of +25.81% and +5.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PODDPositive Net Change QIPTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
D-Wave Quantum Inc. (QBTS) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
D-WAVE QUANTUM (QBTS) delivered earnings and revenue surprises of -816.67% and +22.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
QBTSNegative Net Change AFRMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +2.63% and -0.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CCCCNegative Net Change DARENegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Crocs (CROX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Crocs (CROX) delivered earnings and revenue surprises of +5.49% and +0.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CROXPositive Net Change DLTHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank